BeOne Medicines Ltd. (trading as BEIGENE; stock code 06160) has announced that its Board Audit Committee will convene on 25 March 2026 (Hong Kong time) to review and approve the consolidated annual results for the financial year ended 31 December 2025.

The company previously disclosed the same FY2025 financials in its Form 10-K filed with the U.S. Securities and Exchange Commission on 26 February 2026. The forthcoming Hong Kong release will replicate those figures and include the additional disclosures and the U.S. GAAP-to-IFRS reconciliation mandated by the Hong Kong Listing Rules.

Board composition remains unchanged, with Mr. John V. Oyler serving as Chairman and Executive Director, supported by one Non-executive Director and nine Independent Non-executive Directors.

The announcement clarifies that the Hong Kong publication will comply fully with local listing requirements while maintaining consistency with the previously filed U.S. financial statements.